Safety evaluation of coadministration of erlotinib and theracurmin in non-small cell lung cancer patients
Phase 1
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-UMIN000013424
- Lead Sponsor
- Saitama Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Exclusion Criteria
1)idiopathic pulmonary fibrosis, interstitial pneumonia, radiation pneumonitis, drug related pneumonitis 2)plueral, peritoneal, or pericardial effusion requiring drainage 3)active infection 4)unable to take oral medication 5)symptomatic eye disorders 6)pregnant or lactating 7)symptomatic brain metastasis 8)other malignancies 9)uncontrolled diabetes 10) active complications 11)patients whom physicians judged to be unsuitable for enrollment for other reasons
Study & Design
- Study Type
- Interventional,observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety
- Secondary Outcome Measures
Name Time Method